The United States has agreed to purchase 66 million doses of Moderna’s bivalent COVID-19 booster candidate for $1.74 billion.
Moderna announced that the United States government has agreed to purchase 66 million doses of the company’s COVID-19 vaccine booster candidate, mRNA-1273.222, for $1.74 billion on July 29, 2022. The bivalent candidate contains the Spikvax vaccine as well as the omicron BA.4/5 strain mRNA.
According to a company press release, $1.74 billion will be awarded to Moderna following the manufacture and delivery of 66 million doses of the vaccine. The agreement includes an option for the US to purchase up to an additional 234 million doses of the COVID-19 vaccine booster.
"We are pleased to extend our successful collaboration with the [US] government," said Stéphane Bancel, CEO, Moderna, in the press release. "Moderna's mRNA platform is enabling us to rapidly create mRNA-1273.222, a bivalent vaccine that specifically targets [omicron] subvariants BA.4 and BA.5, the most prevalent variants of concern in the [US] today. We remain fully committed to leveraging our innovative technology platform to offer tailored vaccines that help protect communities against COVID-19."
In addition to mRNA-1273.222, Moderna is also developing mRNA-1273.214. This contains the BA.1 omicron strain, which WHO noted may be of benefit to the public.
Source: Moderna
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.